Search
Patexia Research
Patent No. US 11327071
Issue Date May 10, 2022
Claim this patent
PDF Unavailable

Patent 11327071 - Assessment of preeclampsia using assays for free and dissociated placental growth factor > Claims

  • 1. A method for determining levels of free and dissociated PlGF in a biological sample from a pregnant human female subject, the method comprising: (a) determining an amount of PlGF-f in the biological sample;(b) applying a treatment to the biological sample to dissociate PlGF complexes; and(c) determining an amount of PlGF-d in the biological sample.
    • 2. The method of claim 1, further comprising obtaining the biological sample prior to (a).
    • 3. The method of claim 1, further comprising determining an amount of at least sFLT.
    • 4. The method of claim 1, further comprising determining an amount of Endoglin in the biological sample.
    • 5. The method of claim 1, further comprising determining an amount of KIM-1 in the biological sample.
    • 6. The method of claim 1, further comprising determining an amount of CD274 in the biological sample.
    • 7. The method of claim 1, further comprising determining an amount of FGF21 in the biological sample.
    • 8. The method of claim 1, wherein the treatment comprises contacting the biological sample with an agent that prevents PlGF from assembling into a PlGF complex or disables PlGF from a PlGF:sFLT1 complex.
      • 9. The method of claim 8, wherein the agent is selected from: a surfactant, a detergent, a chaotropic agent, a PlGF-binding protein, and an s-FLT-binding protein.
    • 10. The method of claim 1, wherein the amount of PlGF-f, PlGF-d, or both is determined by an immunoassay.
      • 11. The method of claim 10, wherein the immunoassay is selected from a capture ELISA, an indirect ELISA, a TR-FRET assay, a proximity extension assay, an amplified luminescent proximity (LOCI) assay, an electrochemiluminescence immunoassay, a luminescent oxygen channeling assay, or a lateral flow assay.
    • 12. The method of claim 1, wherein (a) or (c) involve contacting the biological sample with a capture reagent.
      • 13. The method of claim 12, wherein the capture agent comprises an aptamer or an antibody or an antigen-binding fragment thereof.
    • 14. The method of claim 1, wherein the biological sample is serum or plasma.
    • 15. The method of claim 1, wherein the amount of PlGF-f and the amount of PlGF-d are determined using same reagents.
    • 16. The method of claim 1, wherein the pregnant human female has been pregnant for at least 20 weeks.
    • 17. The method of claim 1, wherein the pregnant human female has been pregnant for no more than 30 weeks.
    • 18. The method of claim 1, wherein determining the amount of PLGF-d in the biological sample comprises determining a total amount of PLGF in the biological sample.
Menu